Experience of VA psychiatrists with pharmaceutical detailing of antipsychotic medications

Psychiatric Services

Volumn 58, Issue 10, 2007, Pages 1292-1296

  Sernyak, Michael ^a,b   Rosenheck, Robert ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADVERSE OUTCOME; ARTICLE; CLINICAL PRACTICE; COST CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; EXPERIENCE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; INTERNET; NEGATIVE SYNDROME; NORMAL HUMAN; POSITIVE SYNDROME; PRESCRIPTION; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; PUBLIC HOSPITAL; QUESTIONNAIRE; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

EID: 35748976538     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.10.1292     Document Type: Article

References (27)

1. Lieberman JA, Stamp S, McEvoy J, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. New England Journal of Medicine 353:1209-1223, 2005
2. Jones PB, Barnes TRE, Davies L, et al: Randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006
3. Lieberman JA: Comparative effectiveness of antipsychotic drugs: a commentary on: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Archives of General Psychiatry 63:1069-1072, 2006
4. Please hold the free lunches. New York Times, Aug 4, 2006, p A16
5. Brodkey A: The role of the pharmaceutical industry in teaching psychopharmacology: a growing problem. Academic Psychiatry 29: 222-229, 2005
6. Sierles FS, Brodkey AC, Cleary LM, et al: Medical students' exposure to and attitudes about drug company interactions: a national survey. JAMA 294:1034-1042, 2005
7. Bodenheimer T: Uneasy alliance: clinical investigators and the pharmaceutical industry. New England Journal of Medicine 342:1539-1544, 2000
8. Relman A: Separating continuing medical education from pharmaceutical marketing. JAMA 285:2009-2012, 2001
9. Angell M: Is academic medicine for sale? New England Journal of Medicine 342: 1516-1518, 2000
10. Brennan T, Rothman D, Blank L, et al: Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295:429-433, 2006
11. The PhRMA Code on Interactions With Healthcare Providers. Pharmaceutical Research and Manufacturers of America. Available at www.phrma.org/files/ phrma%20code.pdf
12. The Communication of Ethical Guidelines for Gifts to Physicians From Industry. American Medical Association. Available at www. ama-assn.org/ama/pub/ category/8405.html
13. OIG compliance program guidance for pharmaceutical manufacturers. Federal Register 68:23731-23743, 2003. Available at oig.hhs.gov/authorities/docs/03/ 050503FRCPGphar mac.pdf
14. Elliott C: The drug pushers. Atlantic Monthly, Apr 2006, pp 82-93
15. Dana J, Lowenstein G: A social science perspective on gifts to physicians from industry. JAMA 290:252-255, 2003
16. Wazana A: Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283:373-380, 2000
17. Adair R, Holmgren L: Do drug samples influence resident prescribing behavior? A randomized trial. American Journal of Medicine 118:881-884, 2005
18. Ziegler M, Pauline L, Singer B: The accuracy of drug information from pharmaceutical sales representatives. JAMA 273:1296-1298, 1995
19. Shyer D, Bero L: Characteristics of materials distributed by drug companies: an evaluation of appropriateness. Journal of General Internal Medicine 11:575-583, 1996
20. Lexchin J: What information do physicians receive from pharmaceutical representatives? Canadian Family Physician 43:941-945, 1997
21. Sharfstein S: Antipsychotics, economics, and the press. Psychiatric News 40:3, 2005
22. Zyprexa (olanzapine) prescribing information. Indianapolis, Ind, Eli Lilly and company. Available at pi.lilly.com/us/zyprexa-pi.pdf
23. Risperdal (risperidone) prescribing information. Titusville, NJ, Janssen. Available at www.risperdal.com/risperdal/shared/pi/risperdal.pdf
24. Seroquel (quetiapine) prescribing information. Wilmington, Del, AstraZeneca Pharmaceuticals. Available at www.astrazeneca-us.com/pi/seroquel.pdf
25. Abilify (aripiprazole) prescribing information. Princeton, NJ, Bristol-Myers Squibb Company. Available at www.bms.com/cgi-bin/anybin.pl?sql= select%20PPI%20from%20TBPRODUCTPPI%20where%20PPISE Q=101&key=PPI
26. Geodon (ziprasidone) prescribing information. New York, Pfizer. Available at www.pfiz er.com/pfizer/download/uspigeodon.pdf
27. Avorn J, Chen M, Hartley R: Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Medical Journal 73:4-8, 1982